Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care
Alan T. Hirsch,Michael H. Criqui,Diane Treat-Jacobson,Judith G. Regensteiner,Mark A. Creager,Jeffrey W. Olin,Susan H. Krook,Donald B. Hunninghake,Anthony J. Comerota,M. Eileen Walsh,Mary M. McDermott,William R. Hiatt +11 more
TL;DR: The results demonstrate that underdiagnosis of PAD in primary care practice may be a barrier to effective secondary prevention of the high ischemic cardiovascular risk associated with PAD.
read more
Abstract: ContextPeripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis
that is common and is associated with an increased risk of death and ischemic
events, yet may be underdiagnosed in primary care practice.ObjectiveTo assess the feasibility of detecting PAD in primary care clinics,
patient and physician awareness of PAD, and intensity of risk factor treatment
and use of antiplatelet therapies in primary care clinics.Design and SettingThe PAD Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS)
program, a multicenter, cross-sectional study conducted at 27 sites in 25
cities and 350 primary care practices throughout the United States in June-October
1999.PatientsA total of 6979 patients aged 70 years or older or aged 50 through 69
years with history of cigarette smoking or diabetes were evaluated by history
and by measurement of the ankle-brachial index (ABI). PAD was considered present
if the ABI was 0.90 or less, if it was documented in the medical record, or
if there was a history of limb revascularization. Cardiovascular disease (CVD)
was defined as a history of atherosclerotic coronary, cerebral, or abdominal
aortic aneurysmal disease.Main Outcome MeasuresFrequency of detection of PAD; physician and patient awareness of PAD
diagnosis; treatment intensity in PAD patients compared with treatment of
other forms of CVD and with patients without clinical evidence of atherosclerosis.ResultsPAD was detected in 1865 patients (29%); 825 of these (44%) had PAD
only, without evidence of CVD. Overall, 13% had PAD only, 16% had PAD and
CVD, 24% had CVD only, and 47% had neither PAD nor CVD (the reference group).
There were 457 patients (55%) with newly diagnosed PAD only and 366 (35%)
with PAD and CVD who were newly diagnosed during the survey. Eighty-three
percent of patients with prior PAD were aware of their diagnosis, but only
49% of physicians were aware of this diagnosis. Among patients with PAD, classic
claudication was distinctly uncommon (11%). Patients with PAD had similar
atherosclerosis risk factor profiles compared with those who had CVD. Smoking
behavior was more frequently treated in patients with new (53%) and prior
PAD (51%) only than in those with CVD only (35%; P
<.001). Hypertension was treated less frequently in new (84%) and prior
PAD (88%) only vs CVD only (95%; P <.001) and
hyperlipidemia was treated less frequently in new (44%) and prior PAD (56%)
only vs CVD only (73%, P<.001). Antiplatelet medications
were prescribed less often in patients with new (33%) and prior PAD (54%)
only vs CVD only (71%, P<.001). Treatment intensity
for diabetes and use of hormone replacement therapy in women were similar
across all groups.ConclusionsPrevalence of PAD in primary care practices is high, yet physician awareness
of the PAD diagnosis is relatively low. A simple ABI measurement identified
a large number of patients with previously unrecognized PAD. Atherosclerosis
risk factors were very prevalent in PAD patients, but these patients received
less intensive treatment for lipid disorders and hypertension and were prescribed
antiplatelet therapy less frequently than were patients with CVD. These results
demonstrate that underdiagnosis of PAD in primary care practice may be a barrier
to effective secondary prevention of the high ischemic cardiovascular risk
associated with PAD.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Characterizing the Geographic Distribution of Vascular Surgeons in the United States.
Vamsi Krishna Potluri,Joshua L. Bilello,Shaunak Patel,Silpa Yarra,Mellick T. Sykes,Michael B. Silva +5 more
TL;DR: In this paper , the authors identified vascular surgeons using the Physician Compare National Downloadable file from the Centers for Medicare and Medical Services (CMPW) and found a nationwide shortage of vascular surgeons, with urban and rural areas disproportionately affected negatively.
28
Collateral Growth in the Peripheral Circulation: A Review
TL;DR: This basic science review addresses five questions essential in understanding current problems in collateral growth research and the development of therapeutic interventions.
28
Leveraging the Electronic Health Record to Create an Automated Real-Time Prognostic Tool for Peripheral Arterial Disease.
Adelaide M. Arruda-Olson,Naveed Afzal,Vishnu Priya Mallipeddi,Ahmad Said,Homam Moussa Pacha,Sungrim Moon,Alisha P. Chaudhry,Christopher G. Scott,Kent R. Bailey,Thom W. Rooke,Paul W. Wennberg,Vinod C. Kaggal,Gustavo S. Oderich,Iftikhar J. Kullo,Rick A. Nishimura,Rajeev Chaudhry,Hongfang Liu +16 more
TL;DR: In this paper, the authors present automated individualized risk prediction tools linked to electronic health records (EHRs) for management of patients with peripheral arterial disease (PAD).
27
Diagnosis and risk assessment of lower extremity peripheral arterial disease.
TL;DR: The main diagnostic goal is to establish whether the symptoms are predominantly caused by PAD and to what degree the presenting problem is compounded by other comorbidities, such as diabetic neuropathy, arthritis, or venous disorders.
27
Statin use improves limb salvage after intervention for peripheral arterial disease.
Gaurav Parmar,Zdenek Novak,Emily L. Spangler,Mark A. Patterson,Marc A. Passman,Adam W. Beck,Benjamin J. Pearce +6 more
TL;DR: Statin use in patients with PAD with interventions was associated with improved limb salvage and survival, and efforts are ongoing to increase their use across the health care system.
27
References
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
28.6K
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
6.2K
•Journal Article
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE).
TL;DR: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death.
6K
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs,Michael Clearfield,Stephen E. Weis,Edwin J. Whitney,Deborah R. Shapiro,Polly A. Beere,Alexandra Langendorfer,Evan A. Stein,William Kruyer,Antonio M. Gotto +9 more
TL;DR: Lovastatin reduces the risk for the first acute major coronary event in men and women with average TC and LDL-C levels and below-average HDL- C levels and supports the inclusion of HDL-C in risk-factor assessment and the need for reassessment of the National Cholesterol Program guidelines.
5.5K
Related Papers (5)
Alan T. Hirsch,Ziv J. Haskal,Norman R. Hertzer,Curtis W. Bakal,Mark A. Creager,Jonathan L. Halperin,Loren F. Hiratzka,William R.C. Murphy,Jeffrey W. Olin,Jules B. Puschett,Kenneth Rosenfield,David B. Sacks,James C. Stanley,Lloyd M. Taylor,Christopher J. White,John White,Rodney A. White,Elliott M. Antman,Sidney C. Smith,Cynthia D. Adams,Jeffrey L. Anderson,David P. Faxon,Valentin Fuster,Raymond J. Gibbons,Sharon A. Hunt,Alice K. Jacobs,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel +29 more
F. G. R. Fowkes,Gordon D Murray,Isabella Butcher,C.L. Heald,R.J. Lee,Lloyd E. Chambless,Aaron R. Folsom,Alan T. Hirsch,M. Dramaix,G DeBacker,J.C. Wautrecht,Marcel Kornitzer,A.B. Newman,Mary Cushman,Kim Sutton-Tyrrell,Amanda J Lee,Jackie F. Price,Ralph B. D'Agostino,Joanne M. Murabito,Paul Norman,K. Jamrozik,J D Curb,K. H. Masaki,B.L. Rodriquez,J.M. Dekker,Lex M. Bouter,R.J. Heine,Giel Nijpels,C.D.A. Stehouwer,Luigi Ferrucci,Henri E J H Stoffers,J. D. Hooi,J.A. Knottnerus,Mats Ögren,B. Hedblad,J. C. M. Witteman,Monique M.B. Breteler,M. G. Myriam Hunink,Albert Hofman,M H Criqui,Robert Langer,Arnost Fronek,William R. Hiatt,Richard F. Hamman,Helaine E. Resnick,J. M. Guralnik,Mary M. McDermott +46 more